- Home
- BTMD vs WHWK Comparison
BTMD vs WHWK Comparison
Compare BTMD & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | WHWK |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.4M | 95.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTMD | WHWK |
|---|---|---|
| Price | $2.45 | $2.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | ★ $7.00 |
| AVG Volume (30 Days) | 124.9K | ★ 162.5K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.48 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,645,000.00 | $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $3.34 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $2.32 | $1.39 |
| 52 Week High | $6.36 | $3.81 |
Technical Indicators
Market Signals| Indicator | BTMD | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 51.87 |
| Support Level | $2.56 | $2.40 |
| Resistance Level | $2.80 | $2.85 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 1.14 | 38.52 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.